CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

Rationale and design of a prospective substudy of clinical endpoint adjudication processes within an investigator-reported randomised controlled trial in patients with coronary artery disease: the GLOBAL LEADERS Adjudication Sub-StudY (GLASSY) When, where, and how to target vascular inflammation in the post-CANTOS era? Impact of SYNTAX Score on 10-Year Outcomes After Revascularization for Left Main Coronary Artery Disease Apolipoprotein A-V is a potential target for treating coronary artery disease: evidence from genetic and metabolomic analyses Impact of bleeding during dual antiplatelet therapy in patients with coronary artery disease Hypertension: Do Inflammation and Immunity Hold the Key to Solving this Epidemic? Comprehensive Investigation of Circulating Biomarkers and their Causal Role in Atherosclerosis-related Risk Factors and Clinical Events Evolocumab for Early Reduction of LDL Cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS) Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomized trials 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes
|<<... 127 128 129 130 131 132 133 ...>>|

Original Research2019 Mar 9;9(3):e026053.

JOURNAL：BMJ Open. Article Link

Rationale and design of a prospective substudy of clinical endpoint adjudication processes within an investigator-reported randomised controlled trial in patients with coronary artery disease: the GLOBAL LEADERS Adjudication Sub-StudY (GLASSY)

Leonardi S, Franzone A, Piccolo R et al. Keywords: coronary heart disease; coronary intervention; ischaemic heart disease; myocardial infarction

FULL TEXT PDF

>CBS CBS 2019

> CBS 2019

> CBS 2019 注册

> CBS 2019 会议日程

> CBS 2019 学术征集

> CBS 2019 热点

 CBSMD

> CBSMD 网站注册

> 教育中心

> 荐读文献

> Top 10 阅读文献

> 文献导读
CBS 2019 CBS 2019 主席团 教育中心 科研动态
Copyright ⓒ CBS MD Nanjing China. All rights reserved. 京ICP备16025898号-11
联系我们| Top